DaVita to provide dialysis in Taiwan
Taipei patients to get dialysis treatment from DaVita.
Kidney care specialist DaVita has announced today (January 21st) that it will be forming a partnership with Riches Healthcare (RHC) that will see the leading pharmaceutical company provide dialysis treatment to patients in Taiwan.
Four specialised clinics will be set up in and around the capital city of Taipei, with DaVita taking a majority share in the joint venture as part of its Asian expansion strategy. The venues are currently under the ownership of RHC.
Atul Mathur, president of Asia Pacific at DaVita, said: "This acquisition is an exciting opportunity not only to expand into Taiwan, but also to do so with a well-respected and highly experienced team."
He added that, with the addition of Taiwan, "DaVita is now serving patients in five countries across [Asia]" and that the company hopes to aid Taipei with a number of plans designed to restore clinical excellence to the city.
DaVita's other operations include 1,912 outpatient dialysis centres across the US, which serve approximately 150,000 patients.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.